Filter your search
Prescription Drugs Market ReportsX
Prescription pharmaceuticals are drugs that cannot be sold over-the-counter without a written directive from a licensed physician. The global pharmaceutical market was worth approximately $650 billion (at the manufacturer’s level). The market has continued its recovery from the economic downfall experienced in recent years. Sales for pharmaceuticals increased slightly The largest therapeutic areas in medicine are: cardiovascular disease and blood disorders, neuroscience, infection, cancer, respiratory and inflammation and others. The following reports provide market information for prescription pharmaceuticals.
- $995.00 – $7,990.00Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to […]January 1, 2008$995.00 – $7,000.00Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United […]January 1, 2008$995.00 – $7,990.00Kalorama’s 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products […]December 1, 2007$995.00 – $5,000.00In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off […]October 1, 2007$995.00 – $1,990.00It can be said that pharmaceutical companies face a ‘new era.’ in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there […]October 1, 2007$5,995.00 – $11,990.00This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each […]July 1, 2007$500.00 – $5,990.00Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. Kalorama Information’s: Multiple Sclerosis Treatments: World Market […]June 1, 2007$1,295.00 – $2,995.00SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids. The market, which Zyban […]April 1, 2007$2,995.00 – $5,990.00The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them. These and other developments are covered in Kalorama’s Anti-Infectives, World Markets, Vol. II: […]April 1, 2007$2,500.00 – $5,990.00Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete’s foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which […]March 1, 2007